p.(L576P) -KIT mutation in GIST: Favorable prognosis and sensitive to imatinib?

Abstract excerpt

Exon 11 KIT mutations are found in a majority of gastrointestinal stromal tumors (GIST) and are usually predictive of response to imatinib, a KIT, PDGFRA and ABL inhibitor. Exon 11 mutations with poor sensitivity to imatinib and poor outcome can be observed on rare occasions, including p.(L576P). In silico and in vitro studies suggested a decreased binding affinity for imatinib in p.(L576P) KIT mutations, thereby...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gastrointestinal Stromal Tumors
• Share to KIT gene
• Share to PDGFRA gene